Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 12/20 | 0.64 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442561 | 1.00 | MME (0.64) | MMEGPR139ACE | |
| SCHEMBL7416489 | 0.87 | MME (0.67) | MMEACE | |
| SCHEMBL7416486 | 0.87 | MME (0.67) | MMEACE | |
| SCHEMBL10943157 | 0.79 | GPR139 (0.46) | MMEGPR139ACE | |
| SCHEMBL10943154 | 0.79 | GPR139 (0.46) | MMEGPR139ACE | |
| SCHEMBL7418458 | 0.78 | MME (1.00) | MME | |
| SCHEMBL29384844 | 0.78 | MME (1.00) | MME | |
| SCHEMBL7314977 | 0.78 | MME (1.00) | MME | |
| SCHEMBL10939768 | 0.78 | CTSL (0.45) | MMEGPR139 | |
| SCHEMBL10940275 | 0.78 | CTSL (0.45) | MMEGPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-03-31 | — | — | US | claimed |
| WO-2005016249-A2 | COMPOSITIONS OF A CHROMENE OR PHENYL ACETIC ACID CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN ACE INHIBITOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| EP-0729936-B1 | Process for the synthesis of alpha substituted acrylic acids and N-(mercaptoacyl)amino acids | BIOPROJET SOC CIV (FR) | 1999-07-07 | — | — | EP | claimed |
| US-11619037-B2 | Pre-rinse tank with managed flow release | THERMACO INCORPORATED (US) | 2023-04-04 | — | — | US | disclosed |
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | ACE, ACE2, AGTR2 | MME 76/4885GPR139 3037/4885ACE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.